Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

KIDS vs AVNS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AVNS Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 9–1 Matrix Metrics)

AVNS Overall Winner 6-Pillar Tally: KIDS 2 – 3 AVNS (1 Tie) Matrix Metrics: KIDS 1 – 9 AVNS

As of Nov 19, 2026, Avanos Medical, Inc. (AVNS) is the stronger overall head-to-head candidate over OrthoPediatrics Corp. (KIDS) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). KIDS carries a Unified Composite Score of 45.1/100 (HOLD) at $32.51 (N/M Forward P/E, -8.2% operating margin), whereas AVNS carries 56.7/100 (HOLD) at $24.99 (20.0x Forward P/E, 5.4% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About KIDS vs AVNS
KIDS NASDAQ
OrthoPediatrics Corp. Common Stock
Surgical & Medical Instruments & Apparatus
$32.51
+2.72% 1D
Market Cap $850.2M
TTM Revenue $264M
Forward P/E N/M
Beta / 30D Vol 0.81β · 108% Vol
Unified Composite Score
45.1 / 100 HOLD
Tech 28.0 Fund 40.0 Flow 50.0 Mom 46.3
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (12.1% over 20 days), RSI 64
RSI-14: 64.2 · SMA20: $30.90 · SMA50: $25.86
AVNS NYSE Head-to-Head Winner
Avanos Medical, Inc.
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$24.99
+0.04% 1D
Market Cap $1.2B
TTM Revenue $716M
Forward P/E 20.0x
Beta / 30D Vol 1.22β · 6% Vol
Unified Composite Score
56.7 / 100 HOLD
Tech 75.0 Fund 59.0 Flow 50.0 Mom 46.9
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 57
RSI-14: 57.0 · SMA20: $24.93 · SMA50: $24.90

6-Pillar Scorecard Institutional Category Breakdown (KIDS 2 – 3 AVNS)

Columns: Metric · KIDS · AVNS
1. Valuation Multiples AVNS
Forward P/E N/M 20.0x
Trailing P/E N/M 30.7x
PEG Ratio N/M N/M
EV / Revenue 3.2x 1.6x
2. Growth & Scale KIDS
Revenue Growth (YoY) +18.6% +8.8%
Earnings Growth (YoY) +0.0% -21.7%
TTM Revenue (USD) $264M $716M
Market Cap $850.2M $1.2B
3. Profitability & Quality AVNS
Gross Margin 73.8% 50.0%
Operating Margin -8.2% 5.4%
Net Profit Margin -12.8% -10.4%
Return on Equity (ROE) -9.8% -9.2%
4. Balance Sheet & Cash Flow AVNS
Cash Generation (TTM) $1.1M EBITDA $56M EBITDA
Cash Flow Margin 0.4% EBITDA Mgn 7.8% EBITDA Mgn
Net Cash / Leverage $12.99 Book/Sh · -9.8% ROE $16.76 Book/Sh · -9.2% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 145.1% (100th %ile) 33.0% (50th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Neutral
6. R&D & Supply-Chain Moat KIDS
OpEx & R&D Intensity 82.0% of Rev ($217M) 44.6% of Rev ($319M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: KIDS (1) vs AVNS (9)
Institutional Metric KIDS AVNS Criterion Row Edge
Market Capitalization
Scale
$850.2M $1.2B Larger Scale AVNS
Trailing P/E Ratio
Valuation
N/M 30.7x Lower Multiple AVNS
Forward P/E Ratio
Valuation
N/M 20.0x Lower Multiple AVNS
Revenue Growth (YoY)
Growth
+18.6% +8.8% Higher Growth KIDS
Operating Margin (TTM)
Profitability
-8.2% 5.4% Higher Margin AVNS
Net Profit Margin
Profitability
-12.8% -10.4% Higher Margin AVNS
Return on Equity (ROE)
Capital Efficiency
-9.8% -9.2% Higher ROE AVNS
52-Week Range Position
Momentum
90% ($14–$35) 97% ($9–$25) Stronger Trend AVNS
Beta / 30D Volatility
Risk Regime
0.81β · 108% Vol 1.22β · 6% Vol Lower Realized Risk AVNS
Unified Institutional Score
Composite Signal
45.1 / 100 (HOLD) 56.7 / 100 (HOLD) Higher Composite AVNS
Trailing 12M Revenue (USD)
Operating Scale
$264M $716M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
73.8% 50.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 3.2x EV/Rev N/M PEG · 1.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$1.1M EBITDA ($12.99 Book/Sh · -9.8% ROE) $56M EBITDA ($16.76 Book/Sh · -9.2% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AVNS +1.57 pp
KIDS: -1.41% · AVNS: +0.16%
3M Horizon KIDS +15.28 pp
KIDS: +16.41% · AVNS: +1.13%
6M Horizon AVNS +88.7 pp
KIDS: +2.06% · AVNS: +90.76%
1Y Horizon AVNS +106.92 pp
KIDS: +15.41% · AVNS: +122.33%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on KIDS vs AVNS. Trailing 12-month operating profitability (KIDS -8.2% vs AVNS 5.4%) and valuation multiples (KIDS N/M vs AVNS 20.0x Forward P/E) are benchmarked directly in Pillar 4 below.

KIDS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$264M
Gross Margin73.8%
Op. Margin-8.2%
ROE / Fwd P/E-9.8% · N/M
AVNS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$716M
Gross Margin50.0%
Op. Margin5.4%
ROE / Fwd P/E-9.2% · 20.0x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
KIDS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 145.1%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact KIDS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
AVNS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 33.0%
IV Percentile 50th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AVNS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
KIDS Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $850.2M market capitalization and -8.2% operating margin.
OpEx & R&D Reinvestment 82.0% of Rev ($217M)
90D Engineering Disclosures 0 Published
AVNS Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $1.2B market capitalization and 5.4% operating margin.
OpEx & R&D Reinvestment 44.6% of Rev ($319M)
90D Engineering Disclosures 0 Published

Investor FAQ KIDS vs AVNS Key Questions & Quantitative Answers

As of Nov 19, 2026, Avanos Medical, Inc. (AVNS) is the stronger overall head-to-head candidate over OrthoPediatrics Corp. (KIDS) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). KIDS carries a Unified Composite Score of 45.1/100 (HOLD) at $32.51 (N/M Forward P/E, -8.2% operating margin), whereas AVNS carries 56.7/100 (HOLD) at $24.99 (20.0x Forward P/E, 5.4% operating margin). Technically, KIDS sits in a Markup phase (RSI 64.2, UNCLASSIFIED options structure) and AVNS sits in a Neutral phase (RSI 57.0, UNCLASSIFIED options structure).

KIDS leads the Growth & Scale pillar: KIDS posts +18.6% YoY revenue growth and +0.0% YoY earnings growth on $264M TTM revenue (73.8% gross margin, -8.2% operating margin), compared with AVNS at +8.8% YoY revenue growth and -21.7% YoY earnings growth on $716M TTM revenue (50.0% gross margin, 5.4% operating margin). On trailing 12-month operating scale, KIDS generates $264M in USD-normalized revenue versus $716M for AVNS. In operating R&D and SG&A reinvestment, KIDS deploys 82.0% of Rev ($217M) (0 90-day corporate R&D disclosures) versus 44.6% of Rev ($319M) (0 disclosures) for AVNS.

AVNS screens cheaper on headline valuation multiples. KIDS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.2x EV/Revenue (0.4% EBITDA margin), whereas AVNS trades at 20.0x Forward P/E, 30.7x Trailing P/E, N/M PEG, and 1.6x EV/Revenue (7.8% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against KIDS (-9.8% ROE) versus AVNS (-9.2% ROE) capital efficiency.

In options market volatility and institutional positioning, KIDS carries 145.1% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.81β · 108% Vol realized risk). By comparison, AVNS carries 33.0% implied volatility (50th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.22β · 6% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.